HLB Global Acquires Chronic Metabolic Disease Diagnosis Platform Developer
HLB Global announced on the 9th that it has acquired Barabio, a company developing a diagnostic and management platform for chronic metabolic diseases.
HLB Global became the largest shareholder of Barabio by securing 68% of its shares through an investment of 6 billion KRW.
This investment was made through the acquisition of some existing shares of Barabio and participation in a third-party allotment capital increase.
Barabio is a bio-venture established in 2021 by Professor Ahn Cheol-woo, head of the Diabetes Center at Gangnam Severance Hospital, and is developing a diagnostic and management platform for chronic metabolic diseases including diabetes.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- [Breaking] Park Sukeun, Central Labor Relations Commission Chair: "Some Gaps Narrowed Between Samsung Electronics Labor and Management"
- Is This the Peak? As Others Hesitate..."The Answer Is Clear for Surviving the KOSPI 10,000 Era"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
HLB Global stated, "Through this acquisition, we will target the silver healthcare market focused on geriatric diseases."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
